RXi Pharmaceuticals does not let bad genes stand between you and your health. The company specializes in developing drugs based on RNA interference (RNAi), which cuts off a gene's ability to produce a disease. The company believes its approach can lead to a whole new class of drugs for previously untreatable conditions. Its focus includes anti-scarring, fibrosis, and ocular disease treatments. RXi's pipeline also contains neurological (central nervous system and spinal cord) and oncology (cancer) candidates. The company collaborates with EyeGate and Philips. Biotech firm CytRx, which founded RXi to advance its own studies in RNAi therapeutics, spun it off into a publicly traded company in 2008.